About Caped
Tianjin Caped Medical Equipment Co.,Ltd. is a biotechnology company specializing in the R&D, production, sales, and service of In Vitro Diagnostic (IVD) products,with 20 years of industry experience. We provide comprehensiverapid diagnosis managementsolutions, helping healthcare systems worldwide to improve their efficiency and patient care.
We specialize in the development of high-quality IVD products, including:
- Diagnostic Reagents(Test Strips/Test Kits for Human or Animal)
- Biological Raw Materials
- Diagnostic Equipment
CAPED dedicated to offering customers comprehensive and diversified IVD products and services. Customer needs guide our direction, and we are steadfast in keeping pace with the market, aspiring to become leaders in the field of In Vitro Diagnostic.
Product Series
Featured Products
Why Caped
Professional Manufacturers ，Sell Independently
Efficient Production &Timely Delivery
20 Years Accumulation, Industry Leadership
International Famous Brand Cooperation
Global Sales Network
Professional R&D Team, Customized Design
Latest News and Blog
5 Facts You Need to Know about Mycoplasma pneumoniae
In recent times, there has been a notable increase in cases of pediatric pneumonia linked to Mycoplasma pneumoniae (MP) in several countries, including China, Denmark, France, the Netherlands, and specific regions in the United States. This rise has raised concerns on a global scale. Although MP is known to cause occasional outbreaks, experts believe that the current increase may be more significant than usual, particularly in Europe and Asia, where reported cases have quadrupled compared to previous years. In order to understand what MP is all about, here are 5 facts listed below. 1. MP infections typically present with mild symptoms such as low-grade fever, dry cough, mild shortness of breath (especially during physical activity), and fatigue. The symptoms of Mycoplasma pneumonia (MP) differ from those caused by typical pneumonia bacteria like Streptococcus and Haemophilus. MP infections generally do not exhibit severe shortness of breath, high fever, or productive cough. Instead, patients commonly experience low-grade fever, dry cough, mild shortness of breath (especially during physical activity), and fatigue. MP can sometimes resemble an upper respiratory infection or common cold rather than a lower respiratory infection or pneumonia. The most prominent sign of infection is a dry cough. Other possible symptoms may
Study Finds Single Respiratory Virus May Cause Kawasaki Disease
Study Finds Single Respiratory Virus May Cause Kawasaki Disease New research from the Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago suggests that a single, unidentified respiratory virus may be the cause of Kawasaki disease. This discovery challenges the previous belief that multiple pathogens or toxins could cause the disease, which can lead to serious heart problems in children. 1.Kawasaki Disease Mystery Solved? For over 50 years, the cause of Kawasaki disease has remained unclear. Anne Rowley, MD, a pediatric expert at Lurie Children’s, is the lead author of this study, which was published in Laboratory Investigation. She believes the findings are a major breakthrough. “Our data gives a clear direction to find the virus that causes Kawasaki disease. Identifying it will help improve diagnosis, treatment, and prevention,” Rowley explained. 2.What is Kawasaki Disease? Kawasaki disease is a rare condition, mostly affecting children between the ages of 6 months and 5 years. At Lurie Children’s Hospital, 50-60 new cases are diagnosed each year. The disease can lead to heart problems, with infants being at a higher risk. Currently, there is no test to diagnose Kawasaki disease. Its symptoms include fever, rash, swelling of
CDC Study Identifies Leading Causes of Foodborne Illness in the U.S.
A new study by the CDC reveals which foodborne pathogens are making Americans sick and how many people end up in the hospital or die. This study highlights the importance of advanced diagnostics in understanding the risks associated with foodborne diseases. 1.Background of the Study The Centers for Disease Control and Prevention (CDC), in collaboration with the Colorado School of Public Health, recently published a report on foodborne illnesses. The report estimates the number of illnesses, hospitalizations, and deaths caused by seven key foodborne pathogens in the U.S. in 2019. This information was shared in the CDC’s journal, Emerging Infectious Diseases. Foodborne illnesses are usually reported to public health departments. However, not all patients seek medical help, which makes it challenging to get an accurate count. To address this, the CDC adjusts its data to account for underreporting. The CDC’s most recent estimates are based on new diagnostic methods and better data collection, compared to the last report in 2011. 2.Key Pathogens Studied The study focused on seven main foodborne pathogens that cause illnesses, hospitalizations, and deaths in the U.S. These include: Campylobacter spp. Clostridium perfringens Listeria monocytogenes Norovirus Nontyphoidal Salmonella Shiga toxin-producing Escherichia coli (STEC) Toxoplasma gondii These pathogens
Vanderbilt’s $30M AI Mission: Faster, Smarter Antibody Therapies
1.AI vs Antibodies: A 30MQuest Vanderbilt University Medical Center(VUMC) has secured up to 30 million from the U.S. government’s ARPA-H to revolutionize antibody therapy development using artificial intelligence. The project aims to create an AI-driven platform capable of designing antibodies for any disease target—from cancers to superbugs—faster and cheaper than traditional methods. 2.Why Antibodies Matter Antibodies are proteins made by our immune system to fight invaders like viruses or cancer cells. Monoclonal antibodies (lab-made versions) have transformed medicine, treating diseases from cancer to autoimmune disorders. But discovering these therapies is slow, costly, and often fails. 3.The Problem With Old Methods Traditional antibody discovery relies on sifting through thousands of options—like finding a “needle in a haystack.” It requires specific biological samples (e.g., blood from infected patients) and struggles when pathogens mutate. “Current methods are inefficient and limited,” said Ivelin Georgiev, the project’s lead investigator. 4.AI to the Rescue The Vanderbilt team plans to: Build a massive antibody-antigen atlas with millions of data points. Train AI algorithms to predict effective antibodies. Test the AI’s picks against real-world targets, like cancer and antibiotic-resistant bacteria. 5.LIBRA-Seq: Fueling the AI Engine Key to the project is LIBRA-seq, a Vanderbilt-developed tech that maps how antibodies
Qualification& Certification
Global Partners
